Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors

Prostate

Volumn 70, Issue 12, 2010, Pages 1340-1349

  Festuccia, Claudio ^a   Dondi, Donatella ^b   Piccolella, Margherita ^b   Locatelli, Alessia ^b   Gravina, Giovanni Luca ^a   Tombolini, Vincenzo ^a   Motta, Marcella ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Akt and death receptors; GnRH; Hormone refractory prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CASPASE 8; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; GONADORELIN ANTAGONIST; OZARELIX; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SENSITIZATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL DIVISION; DRUG SYNERGISM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; QUINAZOLINES; TUMOR CELLS, CULTURED;

EID: 77956374604     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21169     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Wagner M, Garzotto M, Lemmon D, Eilers KM, Beer TM. Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer. Urology 2005;65:799.
3. Bare RL, Torti FM. Endocrine therapy of prostate cancer. Cancer Treat Res 1998;94:69-687.
4. Von Minckwitz G, Kaufmann M. New endocrine approaches in the treatment of breast cancer. Biomed Pharmacother 1998;52: 122-132. (Pubitemid 28219159)
5. Redding TW, Schally AV. Inhibition of the pituitary-gonadal axis in nude male mice by continuous administration of LHRH agonists and antagonists. J Endocrinol 1990;126:309-315.
6. Chamson-Reig A, Pignataro OP, Libertun C, Lux-Lantos VA. Alterations in intracellular messengers mobilized by gonadotropin- releasing hormone in an experimental ovarian tumor. Endocrinology 1999;140:3573-3580.
7. Kakar SS, Grantham K, Musgrove LC, Devor D, Sellers JC, Neill JD. Rat gonadotropin-releasing hormone (GnRH) receptor: Tissue expression and hormonal regulation of its mRNA. Mol Cell Endocrinol 1994;101:151-157.
8. Jennes L, Eyigor O, Janovick JA, Conn PM. Brain gonadotropin releasing hormone receptors: Localization and regulation. Recent Prog Horm Res 1997;52:475-490.
9. Boyle TA, Belt-Davis DI, Duello TM. Nucleotide sequence analyses predict that human pituitary and human placental gonadotropin-releasing hormone receptors have identical primary structures. Endocrine 1998;9:281-287.
10. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990;62:96-99.
11. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A, Counis R. The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 1997;71:595-599.
12. Szende B, Csikos A, Szepeshazi K, Neill JD, Mulchahey JJ, Halmos G, Lapis K, Schally AV. The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (DTrp6) LHRH on tumor bearing Syrian golden hamsters. Receptor 1994;4:201-207.
13. Dondi D, Limonta P, Moretti RM, Montagnani Marelli M, Garattini E, Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen- independent prostate cancer cell line DU145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54:4091-4095.
14. Kim JH, Park DC, Kim JW, Choi YK, Lew YO, Kim DH, Jung JK, Lim YA, Namkoong SE. Antitumor effect of GnRH agonist in epithelial ovarian cancer. Gynecol Oncol 1999;74:170-180.
15. Limonta P, Pratesi G, Moretti RM, Montagnani Marelli M, Motta M, Dondi D. Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al. Eur J Cancer 1997; 1141-1148.
16. Kim DK, Yang JS, Maiti K, Hwang JI, Kim K, Seen D, Ahn Y, Lee C, Kang BC, Kwon HB, Cheon J, Seong JY. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells. Cancer Res 2009;69:923-931.
17. Kraus S, Levy G, Hanoch T, Naor Z, Seger R. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: Role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 2004;64:5736-5744.
18. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163. (Pubitemid 29068521)
19. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004;64:337-346.
20. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-α in cancer patients. J Clin Oncol 1988; 6:1328-1334.
21. Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001;299:31-38.
22. Zhang HY, Du ZX, Liu BQ, Gao YY, Meng X, Guan Y, Deng WW, Wang HQ. Tunicamycin enhances TRAIL-induced apoptosis by inhibition of cyclin D1 and the subsequentt downregulation of survivin. Exp Mol Med 2009;41(5):362-369.
23. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C, Bologna M. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 2008;68:965-974.
24. Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T. Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res 2002;8:1251-1257.
25. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 2009.
26. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008;263:14-25.
27. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26:158-165.
28. Yano T, Pinski J, Radulovic S, Schally AV. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1994;91:1701-1705. (Pubitemid 24080273)
29. Sica G, Iacopino F, Settesoldi D, Zelano G. Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur Urol 1999; 35:2-8.
30. Mullen P, Scott WN, Miller WR. Growth inhibition observed following administration of an LHRH agonist to a clonal variant of the MCF-7 breast cancer cell line is accompanied by an accumulation of cells in the G0/G1 phase of the cell cycle. Br J Cancer 1991;63:930-932.
31. Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M. Down-modulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol 2008;33:381-388.
32. Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate 2008;68: 793-801.
33. Dondi D, Festuccia C, Piccolella M, Bologna M, Motta M. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 2006;15:393-400.
34. Fister S, Günthert AR, Aicher B, Paulini KW, Emons G, Gründker C. GnRH-II antagonists induce apoptosis in human endometrial, ovarian, and breast cancer cells via activation of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax. Cancer Res 2009;69:6473-6481.
35. Moretti RM, Montagnani Marelli M, Dondi D, Poletti A, Martini L, Motta M, Limonta P. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 1996;81:3930-3937.
36. Emons G, Muller V, Ortmann O, Schulz KD. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998;65:199-206.
37. Crawford ED, Hou AHED. The role of LHRH antagonists in the treatment of prostate cancer. Oncology (Williston Park) 2009;23: 626-630. Review.
38. Beer TM, Ryan C, Bhat G, Garnick M, Abarelix Study Group. Dose-escalated abarelix in androgen-independent prostate cancer: A phase I study. Anticancer Drugs 2006;17:1075-1079.
39. Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007;29:359-373.
40. Huhtaniemi I, White R, McArdle CA, Persson BE. Will GnRH antagonists improve prostate cancer treatment? Trends Endocrinol Metab 2009;20:43-50. Review.
41. Goodman OB Jr. Is there a role for LHRH antagonists in prostate cancer? Oncology (Williston Park) 2009;23:632, 635.